GlassScriptPhysician profile
Anum Riaz
NPI 1962821413
$5,657.21
in general payments reported to CMS, 2019-2025
49 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $232 · 2021: $622 · 2022: $1,002 · 2023: $1,098 · 2024: $1,801 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,253.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.33 | 2021-2025 | |
| Neurelis, INC. | $588.05 | 2020-2024 | Valtoco |
| Ucb, INC. | $542.88 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Eisai INC. | $383.44 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $380.72 | 2019-2025 | |
| Sk Life Science, INC. | $374.83 | 2021-2024 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $206.90 | 2019-2023 | Austedo Xr, Austedo |
| Pfizer INC. | $199.65 | 2022-2025 | |
| Lundbeck LLC | $196.39 | 2019-2024 | Vyepti, Rexulti |
| Argenx US, INC. | $143.74 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $131.37 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Acadia Pharmaceuticals INC | $105.77 | 2021-2024 | Nuplazid, Daybue |
| Csl Behring | $103.80 | 2023-2024 | Hizentra |
| Jazz Pharmaceuticals INC. | $96.08 | 2023-2024 | Epidiolex |
| Takeda Pharmaceuticals U.S.A., INC. | $95.32 | 2022-2023 | Gammagard |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anum Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.